Interesting drug in Alzheimer's trials

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Interesting drug in Alzheimer's trials

Postby dignan » Thu Apr 17, 2008 6:16 pm

I think this drug is interesting because it is an anti-allergy pill that's been approved in Russia for around 20 years, it is neuroprotective and entering phase 3 trials in alzheimer's.


From Medivation's (the sponsor company) website:

Dimebon is an orally-available, small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer’s disease and Huntington’s disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process.


Medivation's Dimebon Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year

April 17, 2008 - PRNewswire-FirstCall - Medivation today announced that Alzheimer's patients treated with the investigational drug Dimebon showed improvement in the key aspects of cognitive function over a one-year period compared with placebo. The improvement occurred in not only memory and language, but also in more complex functions such as awareness of time and place, and praxis -- the process of getting an idea and initiating and completing a new motor task. These clinical results were generated during a pivotal trial of Dimebon in patients with mild-to-moderate Alzheimer's disease (AD).

The data were presented today during an oral presentation at the 60th Annual Meeting of the American Academy of Neurology (AAN) by Steven H. Ferris, Ph.D., the Gerald J. and Dorothy R. Friedman Professor of Psychiatry at New York University and director of the NYU Alzheimer's Disease Center.

"The finding that Dimebon improved memory, orientation, language and praxis in Alzheimer's disease patients suggests that it provides a broad rather than a selective cognitive benefit," said Dr. Ferris. "This is an important finding given that deficits in memory and thinking are one of the hallmarks of Alzheimer's disease and cause patients and caregivers significant distress."

The data presented at the AAN Annual Meeting included results of an analysis of the 11 subdomains of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), a standardized measure of cognition in patients with AD and one of two endpoints the U.S. Food and Drug Administration (FDA) has used to approve all currently marketed drugs for mild-to-moderate AD. In the study, ADAS-cog was assessed at the beginning of the study and at weeks 12, 26, 39 and 52.

Results showed that Dimebon-treated patients were significantly improved compared with placebo on 9 of the 11 ADAS-cog subdomains after one year of treatment. Benefits were observed in memory (word recall, p=0.04; word recognition, p=0.03; remembering instructions, p=0.10); orientation (p= 0.01); constructional praxis (the ability to copy simple drawings or patterns, p=0.005) and ideational praxis (the ability to perform a familiar but complex sequence of actions, p=0.006); and language (following commands, p<0.0001; naming objects, p<0.0001; word finding, p=0.005; comprehension, p=0.15; overall language, p=0.0002).

"We have recently presented a number of different findings from our first pivotal trial of Dimebon at scientific conferences, demonstrating that this investigational drug has a beneficial impact on the key aspects of Alzheimer's disease -- from behavioral symptoms to thinking and memory problems to impairments in daily function," said Lynn Seely, M.D., chief medical officer of Medivation. "Medivation is committed to rapidly developing Dimebon as a treatment for mild-to-moderate Alzheimer's disease to make it available to the millions of people who suffer from this increasingly prevalent disease, for which new treatment options are desperately needed."

Medivation previously announced efficacy and safety results from the pivotal, 12-month, double-blind, placebo-controlled trial of Dimebon in 183 patients with mild-to-moderate AD. Dimebon improved the clinical course of Alzheimer's disease patients by causing statistically significant improvements over placebo in each of the five primary aspects of the disease -- memory, thinking, activities of daily living, behavior and overall clinical function. Significant gains over placebo were evident after as little as 12 weeks of treatment, and were maintained after both six months and a full year of treatment. In addition, after six months of treatment, Dimebon patients were significantly better on all five disease aspects than they were at the beginning of the study. The real-world impact of these data was evaluated by independent assessment, including caregiver interviews, which confirmed improvement or stabilization in 81 percent of Dimebon-treated patients after six months of treatment. Importantly, Dimebon's overall benefit compared to placebo continued to increase over time, and was larger at one year than at six months.

Dimebon was well-tolerated throughout the entire one-year treatment period. The majority of adverse events were mild, with dry mouth (18.0 percent Dimebon, 1.1 percent placebo) and depressed mood the most common events. There were significantly fewer serious adverse events in the Dimebon group than in the placebo group at one year.

Medivation is planning to initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in mild-to-moderate AD in the second quarter of 2008 with the goal of completing the trial and applying for U.S. and European marketing approval in 2010. The Company is also evaluating Dimebon in an ongoing Phase 2 clinical trial in mild-to-moderate Huntington's disease. Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's and Huntington's diseases, making it a potential treatment for these and other neurodegenerative diseases.

http://investors.medivation.net//Releas ... eID=305347
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 2:00 pm

Advertisement

Re: Interesting drug in Alzheimer's trials

Postby gwa » Fri Apr 18, 2008 6:56 am

dignan wrote:
Results showed that Dimebon-treated patients were significantly improved compared with placebo on 9 of the 11 ADAS-cog subdomains after one year of treatment.



This is monumental for Alzheimer's patients. If I read the same words as it relates to MS patients, I would be kicking up my heels.

gwa
Last edited by gwa on Fri Apr 18, 2008 8:02 am, edited 1 time in total.
User avatar
gwa
Family Elder
 
Posts: 846
Joined: Thu Dec 01, 2005 3:00 pm

Postby Lyon » Fri Apr 18, 2008 7:19 am

.
Last edited by Lyon on Mon Nov 28, 2011 3:23 pm, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 2:00 pm

Postby gibbledygook » Fri Apr 18, 2008 7:55 am

You should be able to buy it off-label from a privat quack, if you can find one.
3 years antibiotics, 06/09 bilateral jug stents at C1, 05/11 ballooning of both jug valves, 07/12 stenting of renal vein, azygos & jug valve ballooning,
User avatar
gibbledygook
Family Elder
 
Posts: 1414
Joined: Mon Feb 14, 2005 3:00 pm
Location: London

Postby Lyon » Fri Apr 18, 2008 8:01 am

.
Last edited by Lyon on Mon Nov 28, 2011 3:22 pm, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 2:00 pm

Postby gwa » Fri Apr 18, 2008 8:31 am

Lyon,

Maybe your mom's doctor would consider putting her on the med if he was acquainted with the new research. Surely the person knows about it if he treats Alzheimer's patients.

The study sounds like a winning proposition, because there were not any significant side effects and most important of all, it actually helped the patients.

gwa
User avatar
gwa
Family Elder
 
Posts: 846
Joined: Thu Dec 01, 2005 3:00 pm

Postby Lyon » Fri Apr 18, 2008 8:51 am

.
Last edited by Lyon on Mon Nov 28, 2011 3:22 pm, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 2:00 pm

Postby dignan » Fri Apr 18, 2008 9:39 am

I think the risk with this one really is minimal...

There were significantly fewer serious adverse events in the Dimebon group than in the placebo group at one year.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 2:00 pm


Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service

cron